MedPath

Cyclophosphamide

Generic Name
Cyclophosphamide
Brand Names
Procytox
Drug Type
Small Molecule
Chemical Formula
C7H15Cl2N2O2P
CAS Number
50-18-0
Unique Ingredient Identifier
6UXW23996M
Background

Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication

Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
Associated Therapies
-

Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia

First Posted Date
2004-05-20
Last Posted Date
2016-07-06
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
163
Registration Number
NCT00003700
Locations
🇺🇸

University of Illinois at Chicago Health Sciences Center, Chicago, Illinois, United States

🇺🇸

University of Chicago Cancer Research Center, Chicago, Illinois, United States

🇺🇸

Veterans Affairs Medical Center - Chicago (Westside Hospital), Chicago, Illinois, United States

and more 47 locations

Chemotherapy With or Without Total-Body Irradiation Prior to Bone Marrow Transplantation in Treating Children With Acute Lymphoblastic Leukemia

Phase 3
Terminated
Conditions
Leukemia
Interventions
Drug: cyclophosphamide
Drug: etoposide
Drug: cyclosporine
Procedure: allogeneic bone marrow transplantation
Radiation: Total Body Irradiation
Drug: methotrexate
Radiation: Radiation
Drug: Busulfan
Drug: Mesna
First Posted Date
2004-05-19
Last Posted Date
2013-10-16
Lead Sponsor
Children's Hospital of Philadelphia
Target Recruit Count
43
Registration Number
NCT00002961
Locations
🇺🇸

Cardinal Glennon Children's Hospital, Saint Louis, Missouri, United States

🇺🇸

Nemours Children's Clinic, Jacksonville, Florida, United States

🇺🇸

Children's Mercy Hospital, Kansas City, Missouri, United States

and more 15 locations

Cisplatin, Etoposide, and Cyclophosphamide in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Phase 2
Completed
Conditions
Lung Cancer
Interventions
First Posted Date
2004-05-17
Last Posted Date
2012-09-05
Lead Sponsor
Gundersen Lutheran Health System
Target Recruit Count
8
Registration Number
NCT00083161
Locations
🇺🇸

Gundersen Lutheran Center for Cancer and Blood, La Crosse, Wisconsin, United States

Metronomic Low-Dose Cyclophosphamide and Methotrexate With or Without Bevacizumab in Treating Women With Metastatic Breast Cancer

Phase 2
Completed
Conditions
Breast Cancer
Interventions
First Posted Date
2004-05-17
Last Posted Date
2019-05-21
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
57
Registration Number
NCT00083031
Locations
🇺🇸

Massachusetts General Hosptial, Boston, Massachusetts, United States

🇺🇸

Sarah Cannon Research Institute, Nashville, Tennessee, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 1 locations

Combination Chemotherapy or Observation Following Surgery in Treating Infants With Neuroblastoma

Phase 2
Completed
Conditions
Neuroblastoma
First Posted Date
2004-05-12
Last Posted Date
2013-12-19
Lead Sponsor
Children's Hospital Medical Center, Cincinnati
Target Recruit Count
44
Registration Number
NCT00002803
Locations
🇩🇪

University of Cologne, Frechen, Germany

Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma

Phase 3
Completed
Conditions
Neuroblastoma
First Posted Date
2004-05-12
Last Posted Date
2013-12-19
Lead Sponsor
Children's Hospital Medical Center, Cincinnati
Target Recruit Count
500
Registration Number
NCT00002802
Locations
🇩🇪

University of Cologne, Frechen, Germany

High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Locally Recurrent or Metastatic Breast Cancer

Phase 3
Completed
Conditions
Breast Cancer
First Posted Date
2004-05-12
Last Posted Date
2014-12-16
Lead Sponsor
UNICANCER
Target Recruit Count
180
Registration Number
NCT00002870
Locations
🇫🇷

Centre Paul Papin, Angers, France

🇫🇷

Clinique Saint Vincent, Besancon, France

🇫🇷

C.H. Bourg En Bresse, Bourg En Bresse, France

and more 29 locations

High-Dose Chemotherapy Followed by Total-Body Irradiation and Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia

Phase 1
Completed
Conditions
Leukemia
First Posted Date
2004-05-11
Last Posted Date
2010-09-15
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
15
Registration Number
NCT00002788
Locations
🇺🇸

Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma

Phase 3
Conditions
Sarcoma
First Posted Date
2004-05-05
Last Posted Date
2013-09-17
Lead Sponsor
University Hospital Muenster
Registration Number
NCT00002516
Locations
🇬🇧

Royal Victoria Infirmary, Newcastle-upon-Tyne, England, United Kingdom

Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma

Phase 2
Withdrawn
Conditions
Lymphoma
First Posted Date
2004-05-04
Last Posted Date
2021-10-27
Lead Sponsor
Medstar Health Research Institute
Registration Number
NCT00006669
Locations
🇺🇸

Washington Cancer Institute, Washington, District of Columbia, United States

🇺🇸

Franklin Square Hospital Center, Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath